Literature DB >> 3597777

Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.

P J Ballem, G M Segal, J R Stratton, T Gernsheimer, J W Adamson, S J Slichter.   

Abstract

Mechanisms of thrombocytopenia were studied in 38 patients with mild to moderately severe chronic autoimmune thrombocytopenia (AITP). 51Cr and 111In-labeled autologous platelet turnover studies and in vitro analysis of committed megakaryocyte progenitors (CFU-Meg) were used as independent measures of platelet production. Autologous 111In-labeled platelet localization studies were performed to assess platelet clearance. Although there was no increase in the frequency of marrow CFU-Meg, a specific increase in the CFU-Meg [3H]TdR suicide rate was seen which was inversely correlated with the platelet count (P less than 0.001). Platelet turnover studies showed significant numbers of patients had inappropriate thrombopoietic responses to their reduced platelet counts. Platelet-associated antibody levels correlated inversely with platelet turnover suggesting that antiplatelet antibody impairs platelet production. The circulating platelet count was best predicted by an index relating platelet production (i.e., turnover) to the spleen-liver platelet clearance that correlated directly with platelet survival (P less than 0.001). In summary, both depressed platelet production and increased platelet clearance by the liver and spleen contribute to the thrombocytopenia of AITP.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3597777      PMCID: PMC442198          DOI: 10.1172/JCI113060

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Pure red cell anemia due to auto antibodies; immune-type of aplastic anemia, erythroblastopenia.

Authors:  C GASSER
Journal:  Sang       Date:  1955

2.  Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads.

Authors:  P Cuatrecasas
Journal:  J Biol Chem       Date:  1970-06       Impact factor: 5.157

3.  Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ.

Authors:  A du P Heyns; P N Badenhorst; M G Lötter; H Pieters; P Wessels; H F Kotzé
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

Review 4.  Autoimmune platelet destruction: idiopathic thrombocytopenic purpura.

Authors:  J G Kelton; S Gibbons
Journal:  Semin Thromb Hemost       Date:  1982-04       Impact factor: 4.180

5.  Polyploid megakaryocytes develop randomly from a multicompartmental system of committed progenitors.

Authors:  J M Paulus; M Prenant; J F Deschamps; M Henry-Amar
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

Review 6.  Chronic idiopathic thrombocytopenic purpura.

Authors:  R McMillan
Journal:  N Engl J Med       Date:  1981-05-07       Impact factor: 91.245

7.  Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP).

Authors:  I Branehög; J Kutti; A Weinfeld
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

8.  Megakaryocytopoiesis in the rat: response to thrombocytopenia induced by exchange transfusion.

Authors:  H Kimura; G M Segal; M Y Lee; J W Adamson
Journal:  Exp Hematol       Date:  1985-11       Impact factor: 3.084

9.  Membrane proteins on human megakaryocytes and platelets identified by monoclonal antibodies.

Authors:  P Thiagarajan; B Perussia; L De Marco; K Wells; G Trinchieri
Journal:  Am J Hematol       Date:  1983-05       Impact factor: 10.047

10.  Left ventricular thrombi: in vivo detection by indium-111 platelet imaging and two dimensional echocardiography.

Authors:  J R Stratton; J L Ritchie; G W Hamilton; K E Hammermeister; L A Harker
Journal:  Am J Cardiol       Date:  1981-04       Impact factor: 2.778

View more
  72 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  HIGH DOSE PULSE DEXAMETHASONE THERAPY IN CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA.

Authors:  Velu Nair; Vivek Chhabra
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 3.  Immune thrombocytopenia: no longer 'idiopathic'.

Authors:  Keith McCrae
Journal:  Cleve Clin J Med       Date:  2011-06       Impact factor: 2.321

4.  Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura.

Authors:  N Katkhouda; S W Grant; E Mavor; M H Friedlander; R V Lord; K Achanta; R Essani; R Mason
Journal:  Surg Endosc       Date:  2001-02-06       Impact factor: 4.584

Review 5.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

6.  Kinetics of megakaryocyte progenitor cells in idiopathic thrombocytopenic purpura.

Authors:  K Dan; S Gomi; T Nomura
Journal:  Blut       Date:  1990-11

Review 7.  Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.

Authors:  Lisa J Toltl; Donald M Arnold
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

Review 8.  Novel clearance mechanisms of platelets.

Authors:  Renata Grozovsky; Karin M Hoffmeister; Hervé Falet
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 9.  Immune thrombocytopenia and pregnancy.

Authors:  Srividhya Sankaran; Susan E Robinson
Journal:  Obstet Med       Date:  2011-10-25

10.  Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.

Authors:  Anil Kumar Tripathi; Ayush Shukla; Sanjay Mishra; Yogendra Singh Yadav; Deependra Kumar Yadav
Journal:  Int J Hematol       Date:  2014-02-14       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.